Clinical Immunoanalyzer Market Introduction

Clinical immunoanalyzer is a diagnostic device used to detect specific analytes in blood or in fluids by employing immunoassay processes such as chemiluminescence immunoassay, enzyme linked fluorescent immunoassay, enzyme linked immunosorbent assay, and radioimmunoassay (RIA). An immunoanalyzer comprises washer, reagent dispenser, auto sampler, and the offered product depending upon the configuration and test options. Few clinical immunoanalyzer products use automated chemical analyser which reduces manual intervention and improves the workflow. These clinical immunoanalyzers are used in hospitals and laboratories for the detection of bacterial infections and viral toxins. These are also used in drug monitoring, allergy testing, as cancer markers and in detecting toxins.

Global Clinical Immunoanalyzer Market: Competitive Landscape

Major players operating in the global clinical immunoanalyzer market include F. Hoffmann-La Roche Ltd., Abbott, Siemens Healthineers, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., bioMérieux SA, Werfen Life, Thermo Fisher Scientific, Inc., Tosoh Corporation, and Randox Laboratories. Strategies adopted by the key players such as mergers & acquisitions, partnerships, joint ventures, and agreements are projected to boost the growth of the global clinical immunoanalyzer market. These players are investing in the development of novel immunoassays in the infectious diseases domain with increasing database on genetics and biomarkers of various infectious pathogens.

Stuck in a Neck-to-Neck Competition with Other Brands? Request a Custom Report on “Clinical Immunoanalyzer Market” here

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. manufactures and supplies a broad range of products for diversified line of life science research and clinical diagnostics. The company is a leader in the life sciences market. It develops, manufactures, and markets approximately 6,000 reagents, apparatus, and laboratory instruments. The instruments portfolio comprises high, medium, and low volume clinical diagnostics such as automated multiplex testing, western blot processing, and others. Its products and systems are utilized to separate complex chemicals and biological materials to identify, analyze, and purify its components. Bio-Rad Laboratories, Inc. has direct distribution in 35 countries, apart from the U.S.

Thermo Fisher Scientific

Founded in 2006, Thermo Fisher Scientific is a global company that engages in the development, manufacture, and commercialization of life sciences products for the health care, pharmaceutical & biotechnology, and life sciences industries. It operates through four segments: specialty diagnostics, analytical instruments, life sciences solutions, and laboratory products & services. The specialty diagnostics segment offers a range of instruments, kits, and reagents for customers in health care, academic institutes, and other service providers. The segment comprises clinical diagnostics, immunodiagnostics, microbiology, and other businesses. Thermo Fisher Scientific offers products and services to more than 400,000 customers across the globe.

bioMérieux SA

bioMérieux SA is a global pioneer in clinical microbiology, offering solutions in two segments; clinical diagnostics and industrial microbiology. The company has a strong distributor network. It provides services in 160 countries, and has presence in around 43 countries. bioMérieux SA has 19 production sites and 20 research & development centers across the globe. The company is a leader in industrial microbiological control and syndrome molecular diagnosis solutions.

Global Clinical Immunoanalyzer Market Dynamics

High Prevalence and Incidence Rates of Chronic and Infectious Diseases to Drive Demand for Clinical Immunoanalyzers

Prevalence of infectious and chronic diseases across the globe drives demand for early diagnosis. Hence, diagnosis of infectious diseases is one of the leading applications of clinical immunoanalyzers. There has been an increase in investment in the development of new assays for diagnosis of various infectious diseases. In April 2017, the U.S. Department of Health and Human Services awarded Siemens Healthineers for the development of Zika virus immunoassay test to be used on its Advia platform of immunoassay analyzers. High prevalence of infectious diseases is projected to drive demand for diagnostic tests. Demand for clinical immunoanalyzers is likely to increase owing to its benefits in monitoring transfusion medicine, such as blood transfusion and organ transplant. Moreover, incidence of endocrinology diseases such as thyroid dysfunction, diabetes mellitus, and also the incidences of osteoporosis is rising owing to changing lifestyles. This is likely to boost demand for clinical immunoanalyzers.

Need an Overview of the Report on Clinical Immunoanalyzer Market? Ask for the Brochure here

Development of New Assays to Expand Application Areas to Boost Market

The increasing knowledge on biomarkers of various chronic diseases has driven industry experts and researchers to apply this information in the development of new assays to expand the applications of automated immunoassay analyzers. Development in the fields of genomics and proteomics has expanded the database of biomarkers used by industry players to develop new assays. For example, a chemiluminescence assay has been developed to test vitamin D deficiency, which was earlier diagnosed through manual ELISA methods. New molecular diagnostic tests are being developed for infectious diseases; however, these tests lack high throughput and short test time features, which make immunoassay analyzers such as ELISA and CLIA the preferred choice. Drug monitoring is another area where automated immunoassay manufacturers are investing to develop new assays that shorten the test time and help in drug monitoring.

Pressure on Laboratories to Reduce Operational & Capital Expenses to Restrain Market

Stringent laws and regulations and decline in reimbursements from the public sector in the developed markets such as the U.S. and countries in Western Europe are inducing independent diagnostic laboratories to reduce capital expenditure. Moreover, factors such as rise in competition and consolidation among hospitals and diagnostic laboratories are anticipated to restrain the market in the near future.

Global Clinical Immunoanalyzer Market Segmentation

Based on technology, the global clinical immunoanalyzer market can be classified into:

  • Chemiluminescence Immunoassay (CLIA)
  • Enzyme Linked Fluorescent Immunoassay (ELFA)
  • Enzyme Linked Immunosorbent Assay (ELISA)
  • Radioimmunoassay (RIA)
  • Others

In terms of application, the global clinical immunoanalyzer market has been categorized into:

  • Cancer Markers
  • Infectious Diseases
  • Cardiac Disease
  • Drug Monitoring
  • Others

Based on end-user, the global clinical immunoanalyzer market has been divided into:

  • Hospitals
  • Diagnostic Laboratories
  • Blood Banks
  • Others

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Clinical Immunoanalyzer Market

Pre Book